Internuclear opthalmoplegia: Difference between revisions

(Redirected page to Internuclear ophthalmoplegia)
Tag: New redirect
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
==Background==
#REDIRECT[[Internuclear ophthalmoplegia]]
[[File:Ino v2.png|thumbnail|Internuclear opthalmoplegia, courtesy of sketchy medicine]]
 
*Disruption of conjugate gaze.
*Results in [[diplopia]] when looking contralateral (to affected eye).
*Localized to Midbrain or Pons.
*Paramedian Pontine Reticular Formation (PPRF) is the conjugate gaze center for horizontal eye movements. Innervates ipsilateral Abducens (CN VI) nucleus. Abducens nucleus signals ipsilateral lateral rectus to contract and sends a second via MLF to contralateral oculomotor (CN III) nucleus, causing contraction on the contralateral medial rectus.
*Lesions in the Medial Longitudinal Fasiculus (MLF) result in intranuclear ophthalmoplegia (INO).
*Associated with one and one-half syndrome (lesion involving the PPRF and ipsilateral MLF)
 
==Clinical Features==
*Weakness in adduction of affected eye with limitation in horizontal gaze.
*May result in horizontal diplopia
*Horizontal nystagmus in unaffected eye
*Convergence remains intact (differentiates CN III palsy from INO)
 
==Differential Diagnosis==
*Multiple Sclerosis (often presents with bilateral internuclear ophthalmoplegia)
*Cerebrovascular disease
*Malignancy located in brainstem and 4th ventricle
*CN III palsy
 
==Evaluation==
*Neurologic exam
*The use of optokinetic tape is highly sensitive for testing for INO
*MRI
 
==Management==
*Symtoms will often resolve on their own. Patients with cerebrovascular disease are less likely to have recovery.
*Patching of eye can aid in relief of diplopia
*Diframpadine, potassium channel blocker, has been used in patients with demyelinating disease
 
==References==
<references/>
Ropper A, Klein J, Samuels M. Adams and Victor's Principles of Neurology 10th Edition. McGraw-Hill Education / Medical; 2014.
<references/>
Serra A, Skelly MM, Jacobs JB, et al. Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. Neurology 2014; 83:192.
 
 
[[Category:Neurology]]
[[Category:Symptoms]]

Latest revision as of 22:36, 2 October 2019